Treatment for Takayasu Arteritis with Pulmonary Artery Issues
Observation of Long Term Effect of Medical and PTPA Treatment on Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
This study is testing if a combination of medication and a special procedure can help people with Takayasu arteritis who have problems with their pulmonary arteries feel better and improve their treatment results.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Sex | All |
| Sponsor | Chinese Pulmonary Vascular Disease Research Group Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05388682 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effects of medical treatment and percutaneous transluminal pulmonary angioplasty on patients with Takayasu arteritis complicated by pulmonary artery involvement. It aims to assess the efficacy of FAPI imaging in predicting disease activity and treatment outcomes. Patients will undergo baseline evaluations using FAPI and FDG to determine the severity of their condition and the potential effectiveness of the interventions.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with Takayasu arteritis that specifically affects the pulmonary arteries.
Not a fit: Patients with pulmonary artery stenosis due to conditions like CTEPH, fibrosing mediastinitis, or congenital pulmonary artery stenosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment strategies for patients suffering from Takayasu arteritis with pulmonary artery involvement.
How similar studies have performed: While there may be limited studies specifically targeting this combination of conditions, the use of percutaneous transluminal pulmonary angioplasty has shown promise in related vascular conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients diagnosed with Takayasu arteries with pulmonary arteries involvement Exclusion Criteria: * Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis
Where this trial is running
Beijing
- Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, China (Recruiting)
Study contacts
- Principal investigator: zhihong Liu, doctor — Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
- Study coordinator: Zhihong Liu, doctor
- Email: zhihongliufuwai@163.com
- Phone: 86-010-88396589
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.